P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) is a specialized vascular interface that restricts the entry of many compounds into brain. This is accomplished through the sealing of vascular endothelial cells together with tight junction proteins to prevent paracellular diffusion. In addition, the BBB has a high degree of expression of numerous efflux transporters which actively extrude compounds back into blood. However, when a metastatic lesion develops in brain the vasculature is typically compromised with increases in passive permeability (blood-tumor barrier; BTB). What is not well documented is to what degree active efflux retains function at the BTB despite the changes observed in passive permeability. In addition, there have been previous reports documenting both increased and decreased expression of P-glycoprotein (P-gp) in lesion vasculature. Herein, we simultaneously administer a passive diffusion marker ((14)C-AIB) and a tracer subject to P-gp efflux (rhodamine 123) into a murine preclinical model of brain metastases of breast cancer. We observed that the metastatic lesions had similar expression (p > 0.05; n = 756-1214 vessels evaluated) at the BBB and the BTB. Moreover, tissue distribution of R123 was not significantly (p > 0.05) different between normal brain and the metastatic lesion. It is possible that the similar expression of P-gp on the BBB and the BTB contribute to this phenomenon. Additionally we observed P-gp expression at the metastatic cancer cells adjacent to the vasculature which may also contribute to reduced R123 uptake into the lesion. The data suggest that despite the disrupted integrity of the BTB, efflux mechanisms appear to be intact, and may be functionally comparable to the normal BBB. The BTB is a significant hurdle to delivering drugs to brain metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 2×
“The microvasculature of the brain is a unique anatomical structure which serves as a homeostatic and regulatory barrier between the blood and the brain parenchyma (Hawkins and Davis, 2005).”
BackgroundInfluentialHoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T., Ohtsuki, S., & Terasaki, T. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23575 · Cited by 254 · cited 2×
“Study supervision Paul R. Lockman”
BackgroundBrain uptake kinetics of nicotine and cotinine after chronic nicotine exposure
Lockman, P. R., McAfee, G., Geldenhuys, W. J., Van der Schyf, C. J., Abbruscato, T. J., & Allen, D. D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085381 · Cited by 51
Self-citation
Cited by
The Translational Significance of the Neurovascular Unit
McConnell, H. L., Kersch, C. N., Woltjer, R. L., & Neuwelt, E. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.760215 · Cited by 314
Zhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04795-z · Cited by 75
“This limitation may stem from efflux by the P-glycoprotein 1 (P-gp), a common multidrug resistant protein abundant in BBB within cancerous tissues, as shown in rats [39].”
BackgroundMiao, T., Ju, X., Zhu, Q., Wang, Y., Guo, Q., Sun, T., Lu, C., & Han, L. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201900259 · Cited by 70
Metadata
- Authors
- Adkins, C. E., Mittapalli, R. K., Manda, V. K., Nounou, M. I., Mohammad, A. S., Terrell, T. B., Bohn, K. A., Yasemin, C., Grothe, T. R., Lockman, J. A., & Lockman, P. R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 136-136
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2056252635
- Cited by
- 69
- References
- 3
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.